The Phase III trial of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd.’s ifinatamab deruxtecan (I-DXd) in small-cell lung cancer (SCLC) will report in 2027, and following the recent misfire with another of the partners’ antibody-drug conjugates, patritumab deruxtecan, they need this one to hit.
Key Takeaways
- Mid-stage data suggest Merck & Co and Daiichi Sankyo’s antibody-drug conjugate ifinatamab deruxtecan could be competitive in small-cell lung cancer.
Fortunately, Merck and Daiichi will be more sanguine about the 2027 readout following encouraging data from a Phase II trial...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?